Cargando…

It’s TIME for a biomarker-driven approach to cancer immunotherapy

Detalles Bibliográficos
Autor principal:	Emens, Leisha A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986195/ https://www.ncbi.nlm.nih.gov/pubmed/27532018 http://dx.doi.org/10.1186/s40425-016-0147-8

Ejemplares similares

Cancer immunotherapy trials: leading a paradigm shift in drug development
por: Emens, Leisha A., et al.
Publicado: (2016)

Targeting adenosine for cancer immunotherapy
por: Leone, Robert D., et al.
Publicado: (2018)

Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer
por: Emens, Leisha A., et al.
Publicado: (2015)

Toward integrative cancer immunotherapy: targeting the tumor microenvironment
por: Emens, Leisha A, et al.
Publicado: (2012)

Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2022)

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
por: Butterfield, Lisa H, et al.
Publicado: (2008)

A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition
por: Arulraj, Theinmozhi, et al.
Publicado: (2023)

TCR diversity – a universal cancer immunotherapy biomarker?
por: McNeel, Douglas G.
Publicado: (2016)

Circulating protein and antibody biomarker for personalized cancer immunotherapy
por: Yuan, Jianda
Publicado: (2016)

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
por: Masucci, Giuseppe V., et al.
Publicado: (2017)

Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012
por: Sunay, Melek Erdinc, et al.
Publicado: (2013)

Preamble to the 2015 SITC immunotherapy biomarkers taskforce
por: Butterfield, Lisa H, et al.
Publicado: (2015)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
por: Emens, Leisha A, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
por: Disis, Mary L, et al.
Publicado: (2023)

Kinetics reshape antitumor immunity: Timing, duration, and combination are of importance for successful cancer immunotherapy
por: Jin, Seung Mo, et al.
Publicado: (2023)

Checkpoint immunotherapy for NK/T cell lymphoma—Time for a showdown?
por: Chan, Jason Yongsheng, et al.
Publicado: (2021)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Real-time data-driven motion correction in PET
por: Kesner, Adam, et al.
Publicado: (2019)

Targetless T cells in cancer immunotherapy
por: thor Straten, Per, et al.
Publicado: (2016)

It’s a long way to the top (if you want to personalize immunotherapy)
por: Haebe, Sarah, et al.
Publicado: (2017)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

Defining the critical hurdles in cancer immunotherapy
por: Fox, Bernard A, et al.
Publicado: (2011)

HSP70-based anti-cancer immunotherapy
por: Guzhova, Irina V., et al.
Publicado: (2016)

Cancer immunotherapy: avoiding the road to perdition
por: Chiriva-Internati, Maurizio, et al.
Publicado: (2004)

How to select cancer patients for immunotherapy
por: Pfeiffer, Per, et al.
Publicado: (2021)

Ferroptosis: friend or foe in cancer immunotherapy?
por: Demuynck, Robin, et al.
Publicado: (2023)

Dietary and health biomarkers—time for an update
por: Dragsted, Lars O., et al.
Publicado: (2017)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
por: Mirjačić Martinović, Katarina, et al.
Publicado: (2023)

Anti-TNF, a magic bullet in cancer immunotherapy?
por: Montfort, Anne, et al.
Publicado: (2019)

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
por: Visconti, Roberta, et al.
Publicado: (2017)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer
por: Parikh, Mamta, et al.
Publicado: (2022)

A holistic approach to predicting diabetes risk via biomarkers
por: Cohen, Alan A.
Publicado: (2021)

CXCR3: Here to stay to enhance cancer immunotherapy?
por: Rogava, Meri, et al.
Publicado: (2019)

COVID-19: the use of immunotherapy in metastatic lung cancer
por: Davis, Alexander P, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_shgnfmhmnabstphc3geuhaqajg